N. Liptrott

发表

Determining the relationship between nanoparticle characteristics and immunotoxicity: key challenges and approaches.

Andrew Owen, Neill J Liptrott, Christopher A. W. David, 2016, Nanomedicine.

Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics

Lee M. Tatham, Christopher A. W. David, S. Khoo, 2020, medRxiv.

Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis

Lee M. Tatham, Christopher A. W. David, S. Khoo, 2020, medRxiv.

Dose prediction for repurposing nitazoxanide in SARS‐CoV‐2 treatment or chemoprophylaxis

Lee M. Tatham, Christopher A. W. David, S. Khoo, 2020, British journal of clinical pharmacology.

Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies

Darren L. Smith, Tom O. McDonald, S. Rannard, 2016, Nature Communications.

Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation

Darren L. Smith, Tom O. McDonald, S. Khoo, 2014, Advanced healthcare materials.

Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a 'mixed matrix'.

D. Fernig, S. Rannard, A. Owen, 2014, Nanomedicine.

Assessment of changes in autophagic vesicles in human immune cell lines exposed to nano particles

Christopher A. W. David, D. Fernig, M. Rosseinsky, 2021, Cell & bioscience.

High-throughput nanoprecipitation of the organic antimicrobial triclosan and enhancement of activity against Escherichia coli.

Tom O. McDonald, S. Rannard, A. Owen, 2013, Journal of materials chemistry. B.

Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems

Tom O. McDonald, S. Rannard, A. Owen, 2018, Journal of Nanobiotechnology.

Overview of the blood compatibility of nanomedicines: A trend analysis of in vitro and in vivo studies

S. Bremer, N. Liptrott, P. Urban, 2018, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

Functionalized superparamagnetic iron oxide nanoparticles provide highly efficient iron-labeling in macrophages for magnetic resonance–based detection in vivo

Amy E. Chadwick, D. Adams, C. Goldring, 2017, Cytotherapy.

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

S. Khoo, Chloe E. James, A. Owen, 2010, Pharmacogenetics and genomics.

Cytotoxic chemotherapy and the evolution of cellular and viral resistance to antiretroviral therapy in HIV- infected individuals with lymphoma

A. Owen, N. Liptrott, M. Boffito, 2016, HIV clinical trials.

Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system.

Tom O. McDonald, S. Rannard, A. Owen, 2017, Nanomedicine.

Genetic Variants of ABCC10 Are Associated with Kidney Tubular Dysfunction in Patients Treated with Tenofovir-containing Regimens

S. Pushpakom, S. Khoo, A. Owen, 2010 .

Interactions between tenofovir and nevirapine in CD4+ T cells and monocyte-derived macrophages restrict their intracellular accumulation.

S. Khoo, A. Owen, N. Liptrott, 2013, The Journal of antimicrobial chemotherapy.

Towards a rational design of solid drug nanoparticles with optimised pharmacological properties

Darren L. Smith, Tom O. McDonald, S. Rannard, 2016, Journal of interdisciplinary nanomedicine.

Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation

Christopher A. W. David, F. Caputo, R. Vandebriel, 2021, Journal of controlled release : official journal of the Controlled Release Society.

Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions.

Lee M. Tatham, S. Rannard, A. Owen, 2015, Nanomedicine.

In Vitro Determination of the Immunogenic Impact of Nanomaterials on Primary Peripheral Blood Mononuclear Cells

Christopher A. W. David, M. Rosseinsky, C. David, 2020, International journal of molecular sciences.

Safety assessment of a new nanoemulsion-based drug-delivery system reveals unexpected, drug-free, anticoagulant activity.

S. Rannard, A. Owen, N. Liptrott, 2020, Nanomedicine.

The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?

A. Owen, N. Liptrott, 2011, Expert opinion on drug metabolism & toxicology.

Nanomedicines for HIV therapy.

Tom O. McDonald, S. Rannard, A. Owen, 2013, Therapeutic delivery.

Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients

B. Clotet, N. Liptrott, D. Back, 2010, Antimicrobial Agents and Chemotherapy.

In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line

Tom O. McDonald, S. Rannard, D. Dickens, 2017 .

An inter-laboratory comparison of an NLRP3 inflammasome activation assay and dendritic cell maturation assay using a nanostructured lipid carrier and a polymeric nanomedicine, as exemplars

Christopher A. W. David, R. Vandebriel, C. David, 2022, Drug Delivery and Translational Research.

Physiologically based pharmacokinetic modeling of intravenously administered nanoformulated substances

R. Vandebriel, C. Delmaar, N. Liptrott, 2022, Drug Delivery and Translational Research.

Intravenous Administration of Human Umbilical Cord Mesenchymal Stromal Cells Leads to an Inflammatory Response in the Lung

N. Liptrott, P. Murray, B. Wilm, 2022, bioRxiv.

Exposure of the Basophilic Cell Line KU812 to Liposomes Reveals Activation Profiles Associated with Potential Anaphylactic Responses Linked to Physico-Chemical Characteristics

Christopher A. W. David, Y. Perrie, C. David, 2022, Pharmaceutics.

Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection.

Tom O. McDonald, Christopher A. W. David, S. Rannard, 2021, Nanoscale.

Toxicity and inflammatory response in Swiss albino mice after intraperitoneal and oral administration of polyurethane nanoparticles.

F. Filippin-Monteiro, A. H. Silva, A. Owen, 2016, Toxicology letters.

The Application of Nanotechnology to Drug Delivery in Medicine

Andrew Owen, Marco Siccardi, Marco Giardiello, 2015 .

Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics

Lee M. Tatham, Christopher A. W. David, S. Khoo, 2020, Clinical pharmacology and therapeutics.

Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19

Christopher A. W. David, C. David, A. Owen, 2021, Advanced Drug Delivery Reviews.

Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals

B. Gazzard, S. Khoo, N. Liptrott, 2011, Journal of acquired immune deficiency syndromes.

Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation

S. Letendre, A. Owen, N. Liptrott, 2016, Antimicrobial Agents and Chemotherapy.

Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter

A. Owen, N. Liptrott, M. Siccardi, 2015, Front. Pharmacol..

Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach.

A. Owen, N. Liptrott, M. Siccardi, 2018, Drug metabolism and pharmacokinetics.

Fate of intravenously administered umbilical cord mesenchymal stromal cells and interactions with the host's immune system.

N. Liptrott, Arthur Taylor, P. Murray, 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Firefly luciferase offers superior performance to AkaLuc for tracking the fate of administered cell therapies

N. Liptrott, A. Plagge, Arthur Taylor, 2021, European Journal of Nuclear Medicine and Molecular Imaging.

Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS

M. Pirmohamed, S. Pushpakom, S. Khoo, 2012, Pharmacogenetics and genomics.

Critical considerations for targeting colorectal liver metastases with nanotechnology

C. Goldring, S. Rannard, A. Owen, 2019, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

Long-Acting Injectable Statins—Is It Time for a Paradigm Shift?

Lee M. Tatham, S. Rannard, A. Owen, 2019, Molecules.

Immunotoxicity Considerations for Next Generation Cancer Nanomedicines

Adriele Prina-Mello, Gary Hannon, Joanne Lysaght, 2019, Advanced science.

Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates

A. Owen, N. Liptrott, M. Siccardi, 2017, Pharmacology research & perspectives.

Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir

Darren L. Smith, S. Khoo, A. Owen, 2010, Antimicrobial Agents and Chemotherapy.

IFN-&ggr; 874A>T Genotype Is Associated With Higher CCR5 Expression in Peripheral Blood Mononuclear Cells From HIV+ Patients

A. Owen, N. Liptrott, D. Back, 2011, Journal of acquired immune deficiency syndromes.

Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction.

M. Pirmohamed, V. Soriano, S. Pushpakom, 2011, The Journal of infectious diseases.

Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry.

S. Khoo, A. Owen, N. Liptrott, 2008, Journal of immunological methods.

Induction of Cytokines by Nucleic Acid Nanoparticles (NANPs) Depends on the Type of Delivery Carrier

M. Dobrovolskaia, K. Afonin, Morgan Chandler, 2021, Molecules.

Advances in nanomedicine drug delivery applications for HIV therapy

A. Owen, N. Liptrott, P. Curley, 2017, Future science OA.

Exposure of human immune cells, to the antiretrovirals efavirenz and lopinavir, leads to lower glucose uptake and altered bioenergetic cell profiles through interactions with SLC2A1.

Amy E. Chadwick, Christopher A. W. David, N. Liptrott, 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Opportunities and Challenges in Nanotechnology-enabled Antiretroviral Delivery

Andrew Owen, Neill J. Liptrott, Paul Curley, 2016 .

Raltegravir Is a Substrate for the Influx Transporters OAT1 and PEPT1 and the Efflux Transporter Pgp, but Is Not Transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2

S. Khoo, A. Owen, N. Liptrott, 2010 .

Bridging communities in the field of nanomedicine

Thierry Bastogne, Valérie Zuang, Patrick Boisseau, 2019, Regulatory toxicology and pharmacology : RTP.

Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations

Lee M. Tatham, Christopher A. W. David, C. Flexner, 2023, Pharmaceutics.

Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 In Vitro

A. Owen, N. Liptrott, D. Back, 2013, Antimicrobial Agents and Chemotherapy.

Rilpivirine Inhibits Drug Transporters ABCB 1 , SLC 22 A 1 , and SLC 22 A 2 In Vitro

A. Owen, N. Liptrott, D. Back, 2013 .

ABCB1, SLC22A1, and SLC22A2 Rilpivirine Inhibits Drug Transporters

N. Liptrott, P. Curley, D. Moss, 2014 .

AUTOSTERE: Systematic Search for Scaffold Replacement Opportunities within Structural Databases

Joseph M. Sheridan, Saye Khoo, Jonathan R. Heal, 2021, J. Chem. Inf. Model..

Age differential CD13 and interferon expression in airway epithelia affect SARS-CoV-2 infection - effects of vitamin D.

N. Liptrott, G. Biagini, F. Sposito, 2023, Mucosal immunology.

Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir

Darren L. Smith, S. Khoo, A. Owen, 2010, Antimicrobial Agents and Chemotherapy.